Outcomes for Children With Type II and Type III Pleuropulmonary Blastoma Following Chemotherapy: A Report From the International PPB/ DICER1 Registry.

Autor:	Schultz KAP; International Pleuropulmonary Blastoma/DICER1 Registry, Children's Minnesota, Minneapolis, MN.; International Ovarian and Testicular Stromal Tumor Registry, Children's Minnesota, Minneapolis, MN.; Cancer and Blood Disorders, Children's Minnesota, Minneapolis, MN., Harris AK; International Pleuropulmonary Blastoma/DICER1 Registry, Children's Minnesota, Minneapolis, MN.; International Ovarian and Testicular Stromal Tumor Registry, Children's Minnesota, Minneapolis, MN.; Cancer and Blood Disorders, Children's Minnesota, Minneapolis, MN., Nelson AT; International Pleuropulmonary Blastoma/DICER1 Registry, Children's Minnesota, Minneapolis, MN.; International Ovarian and Testicular Stromal Tumor Registry, Children's Minnesota, Minneapolis, MN.; Cancer and Blood Disorders, Children's Minnesota, Minneapolis, MN.; University of Minnesota Medical School, Minneapolis, MN., Watson D; Research Institute, Children's Minnesota, Minneapolis, MN., Lucas JT Jr; Department of Radiation Oncology, St Jude Children's Research Hospital, Memphis, TN., Miniati D; Division of Pediatric Surgery, Kaiser Permanente Northern California, Roseville, CA., Stewart DR; Clinical Genetics Branch, Division of Cancer Epidemiology and Genetics, National Cancer Institute, Rockville, MD., Hagedorn KN; Department of Radiology, Children's Minnesota, Minneapolis, MN., Mize W; Department of Radiology, Children's Minnesota, Minneapolis, MN., Kamihara J; Pediatric Oncology, Dana-Farber/Boston Children's Cancer and Blood Disorders Center, Harvard Medical School, Boston, MA., Mitchell SG; Aflac Cancer and Blood Disorders Center, Children's Healthcare of Atlanta, Emory University School of Medicine, Atlanta, GA., Wilson DB; Department of Pediatrics, Washington University School of Medicine, St Louis Children's Hospital, St Louis, MO., Gettinger K; Department of Pediatrics, Washington University School of Medicine, St Louis Children's Hospital, St Louis, MO., Rangaswami AA; Division of Pediatric Hematology and Oncology, University of California San Francisco, San Francisco, CA., Harney LA; Westat, Rockville, MD., Rodriguez Galindo C; Department of Global Pediatric Medicine, St Jude Children's Research Hospital, Memphis, TN., Bisogno G; Hematology, Oncology and Stem Cell Transplant Division, Department of Women's and Children's Health, University of Padova, Padova, Italy., Dehner LP; Lauren V. Ackerman Laboratory of Surgical Pathology, Department of Pathology and Immunology, Washington University School of Medicine, St Louis, MO., Hill DA; Division of Pathology, Children's National Medical Center, George Washington University School of Medicine and Health Sciences, Washington, DC.; ResourcePath LLC, Sterling, VA., Messinger YH; International Pleuropulmonary Blastoma/DICER1 Registry, Children's Minnesota, Minneapolis, MN.; International Ovarian and Testicular Stromal Tumor Registry, Children's Minnesota, Minneapolis, MN.; Cancer and Blood Disorders, Children's Minnesota, Minneapolis, MN.
Jazyk:	angličtina
Zdroj:	Journal of clinical oncology : official journal of the American Society of Clinical Oncology [J Clin Oncol] 2023 Feb 01; Vol. 41 (4), pp. 778-789. Date of Electronic Publication: 2022 Sep 22.
DOI:	10.1200/JCO.21.02925
Abstrakt:	Purpose: Pleuropulmonary blastoma (PPB) is the most common primary lung neoplasm of infancy and early childhood. Type II and type III PPB have historically been associated with a poor prognosis. Methods: Patients with known or suspected PPB were enrolled in the International PPB/ DICER1 Registry. Medical records were abstracted with follow-up ascertained annually. All PPB diagnoses were confirmed by central pathology review. Beginning in 2007, the IVADo regimen (ifosfamide, vincristine, actinomycin-D, and doxorubicin) was recommended as a potential treatment regimen for children with type II and type III PPB. This regimen was compared with a historical control cohort. Results: From 1987 to 2021, 314 children with centrally confirmed type II and type III PPB who received upfront chemotherapy were enrolled; 132 children (75 with type II and 57 with type III) received IVADo chemotherapy. Adjusted analyses suggest improved overall survival for children treated with IVADo in comparison with historical controls with an estimated hazard ratio of 0.65 (95% CI, 0.39 to 1.08). Compared with localized disease, distant metastasis at diagnosis was associated with worse PPB event-free survival and overall survival with hazard ratio of 4.23 (95% CI, 2.42 to 7.38) and 4.69 (95% CI, 2.50 to 8.80), respectively. Conclusion: The use of IVADo in children with type II and type III PPB resulted in similar-to-improved outcomes compared with historical controls. Inferior outcomes with metastatic disease suggest the need for novel therapies. This large cohort of uniformly treated children with advanced PPB serves as a benchmark for future multicenter therapeutic studies for this rare pediatric tumor.
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu